HPTN 103 Protocol Leadership support
Date:
08/01/2022
Lead Investigators:
Summary
Sunil Solomon is Protocol Chair for HPTN 103/PURPOSE 4, a Phase 2, open-label, multicenter, randomized study to evaluate the pharmacokinetics and safety of twice-yearly long-acting subcutaneous lenacapavir for pre-exposure prophylaxis in people who inject drugs.